cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Amgen Inc
205 own
64 watching
Current Price
$273.54
$1.63
(0.6%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
150,311.82M
52-Week High
52-Week High
329.72000
52-Week Low
52-Week Low
211.71001
Average Volume
Average Volume
2.4M
Dividend Yield
Dividend Yield
0.032184
P/E Ratio
P/E Ratio
21.7238
iconMarket Capitalization150,311.82M
icon52-Week High329.72000
icon52-Week Low211.71001
iconAverage Volume2.4M
iconDividend Yield0.032184
iconP/E Ratio21.7238
What does the Amgen Inc do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Read More
How much money does Amgen Inc make?
News & Events about Amgen Inc.
InvestorPlace
9 months ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025 The post 3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025 appeared first on ...
Zolmax
10 months ago
Byrne Asset Management LLC lifted its position in Amgen Inc. (NASDAQ:AMGN Get Rating) by 22.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,166 shares of the medical research companys stock after acquiring an ...
PR Newswire
10 months ago
FDA GRANTS FULL APPROVAL FOR BLINCYTO (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FDA GRANTS FULL APPROVAL FOR BLINCYTO (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PR Newswire...
Ticker Report
10 months ago
Mission Wealth Management LP raised its stake in Amgen Inc. (NASDAQ:AMGN Get Rating) by 2.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,073 shares of the medical research companys stock after ...
Ticker Report
10 months ago
Cedar Brook Financial Partners LLC reduced its holdings in Amgen Inc. (NASDAQ:AMGN Get Rating) by 11.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 903 shares of the medical research companys stock ...
Frequently Asked Questions
Frequently Asked Questions
What is Amgen Inc share price today?
plus_minus_icon
Can Indians buy Amgen Inc shares?
plus_minus_icon
How can I buy Amgen Inc shares from India?
plus_minus_icon
Can Fractional shares of Amgen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Amgen Inc stocks?
plus_minus_icon
What is today’s traded volume of Amgen Inc?
plus_minus_icon
What is today’s market capitalisation of Amgen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Amgen Inc?
plus_minus_icon
What percentage is Amgen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Amgen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$273.54
$1.63
(0.6%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00